Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
Status:
Not yet recruiting
Trial end date:
2027-01-03
Target enrollment:
Participant gender:
Summary
The primary goal of the trial is to determine if the experimental arms (rivaroxaban or
ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of
ischemic stroke, intracerebral hemorrhage, or vascular death.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University of Florida
Collaborators:
AstraZeneca Janssen Scientific Affairs, LLC Medical University of South Carolina National Institute of Neurological Disorders and Stroke (NINDS) University of Cincinnati